

# Wei-Jun Wei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8708144/publications.pdf>

Version: 2024-02-01

52  
papers

1,466  
citations

361045

20  
h-index

344852

36  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2229  
citing authors

#	ARTICLE	IF	CITATIONS
1	ImmunoPET: Concept, Design, and Applications. <i>Chemical Reviews</i> , 2020, 120, 3787-3851.	23.0	263
2	Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. <i>Journal of the American Chemical Society</i> , 2018, 140, 14971-14979.	6.6	148
3	Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. <i>European Journal of Endocrinology</i> , 2015, 173, 399-408.	1.9	93
4	Noninvasive PET Imaging of T cells. <i>Trends in Cancer</i> , 2018, 4, 359-373.	3.8	88
5	Comparison of SPET/CT, SPET and planar imaging using <sup>99m</sup> Tc-MIBI as independent techniques to support minimally invasive parathyroidectomy in primary hyperparathyroidism: A meta-analysis. <i>Hellenic Journal of Nuclear Medicine</i> , 2015, 18, 127-35.	0.2	46
6	Molecular imaging of $\beta^2$ -cells: diabetes and beyond. <i>Advanced Drug Delivery Reviews</i> , 2019, 139, 16-31.	6.6	42
7	CD146-targeted Multimodal Image-guided Photoimmunotherapy of Melanoma. <i>Advanced Science</i> , 2019, 6, 1801237.	5.6	42
8	Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting <sup>131</sup> I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 1377-1390.	1.1	35
9	miRNA-106a directly targeting RARB associates with the expression of Na <sup>+</sup> /I <sup>-</sup> symporter in thyroid cancer by regulating MAPK signaling pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 101.	3.5	35
10	PET Imaging of Receptor Tyrosine Kinases in Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1625-1636.	1.9	35
11	ImmunoPET imaging of multiple myeloma with [ <sup>68</sup> Ga]Ga-NOTA-Nb1053. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2749-2760.	3.3	34
12	A distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2017, 87, 844-852.	1.2	33
13	Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 718-730.	1.1	31
14	ImmunoPET imaging of human CD8 <sup>+</sup> T cells with novel <sup>68</sup> Ga-labeled nanobody companion diagnostic agents. <i>Journal of Nanobiotechnology</i> , 2021, 19, 42.	4.2	30
15	PET and SPECT imaging of melanoma: the state of the art. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 132-150.	3.3	29
16	Obatoclox and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. <i>Theranostics</i> , 2017, 7, 987-1001.	4.6	28
17	Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?. <i>Endocrine</i> , 2017, 58, 176-183.	1.1	25
18	Exploiting Nanomaterial-mediated Autophagy for Cancer Therapy. <i>Small Methods</i> , 2019, 3, 1800365.	4.6	25

#	ARTICLE	IF	CITATIONS
19	GPC3-targeted immunoPET imaging of hepatocellular carcinomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2682-2692.	3.3	23
20	Differential expression profiling of circulation microRNAs in PTC patients with non- 131 I and 131 I-avid lungs metastases: a pilot study. <i>Nuclear Medicine and Biology</i> , 2015, 42, 499-504.	0.3	22
21	Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo. <i>Journal of Molecular Endocrinology</i> , 2017, 58, 15-23.	1.1	22
22	Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy?. <i>European Radiology</i> , 2019, 29, 3945-3954.	2.3	22
23	Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer. <i>Advanced Science</i> , 2020, 7, 1903595.	5.6	22
24	Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. <i>Oncology Reports</i> , 2016, 36, 1576-1584.	1.2	21
25	Afamin promotes glucose metabolism in papillary thyroid carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2016, 434, 108-115.	1.6	20
26	MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: a systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2016, 84, 127-133.	1.2	18
27	Targeting autophagy in thyroid cancers. <i>Endocrine-Related Cancer</i> , 2019, 26, R181-R194.	1.6	18
28	Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131I. <i>Endocrine</i> , 2018, 62, 149-158.	1.1	17
29	Programmed Cell Death-1 Ligand 1 Overexpression in Thyroid Cancer. <i>Endocrine Practice</i> , 2019, 25, 279-286.	1.1	16
30	Engineering nanobodies for next-generation molecular imaging. <i>Drug Discovery Today</i> , 2022, 27, 1622-1638.	3.2	16
31	Development and characterization of CD54-targeted immunoPET imaging in solid tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2765-2775.	3.3	15
32	ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2737-2748.	3.3	14
33	Single-Domain Antibody Theranostics on the Horizon. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1475-1479.	2.8	14
34	ImmunoPET Imaging of TIM-3 in Murine Melanoma Models. <i>Advanced Therapeutics</i> , 2020, 3, 2000018.	1.6	12
35	Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. <i>American Journal of Cancer Research</i> , 2019, 9, 1454-1468.	1.4	11
36	Value of post-therapeutic 131I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma. <i>Endocrine</i> , 2016, 51, 283-290.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level. <i>Scientific Reports</i> , 2017, 7, 2849.	1.6	10
38	Postsurgical Management of Differentiated Thyroid Cancer in China. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 71-73.	3.1	10
39	HER2-targeted multimodal imaging of anaplastic thyroid cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 2413-2427.	1.4	10
40	Annotating CD38 Expression in Multiple Myeloma with [ <sup>18</sup> F]Fâ€“Nb1053. <i>Molecular Pharmaceutics</i> , 2022, 19, 3502-3510.	2.3	10
41	ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality. <i>Drug Discovery Today</i> , 2022, 27, 1196-1203.	3.2	9
42	A Preliminary Study of Ankle Single Photon Emission Computed Tomography/Computed Tomography in Patients With Bony Impingement Syndrome: Association With the Visual Analogue Scale Pain Score. <i>Journal of Foot and Ankle Surgery</i> , 2019, 58, 434-440.	0.5	8
43	Annotating BCMA Expression in Multiple Myelomas. <i>Molecular Pharmaceutics</i> , 2022, 19, 3492-3501.	2.3	7
44	Next-Generation Molecular Imaging of Thyroid Cancer. <i>Cancers</i> , 2021, 13, 3188.	1.7	6
45	Dual time-point 18F-FDG PET/CT imaging with multiple metabolic parameters in the differential diagnosis of malignancy-suspected bone/joint lesions. <i>Oncotarget</i> , 2017, 8, 71188-71196.	0.8	5
46	Molecular Imaging of Renal Cell Carcinoma in Precision Medicine. <i>Molecular Pharmaceutics</i> , 2022, 19, 3457-3470.	2.3	5
47	PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. <i>Molecular Pharmaceutics</i> , 2022, 19, 3471-3483.	2.3	4
48	Value of Tc-MDP SPECT/CT and F-FDG PET/CT scanning in the evaluation of malignantly transformed fibrous dysplasia. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 92-104.	1.0	3
49	Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e405-e406.	0.7	2
50	Metastatic Malignant Fibrous Histiocytoma Infiltrating Sigmoid Colon. <i>Clinical Nuclear Medicine</i> , 2016, 41, 338-340.	0.7	1
51	Myofibrosarcoma infiltrating pulmonary arteries diagnosed on 18F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 1429.	3.3	0
52	Advancing the diagnosis of epithelioid hemangioendothelioma by F-FDG PET/CT. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 230-232.	1.0	0